ATE423136T1 - Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor - Google Patents

Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor

Info

Publication number
ATE423136T1
ATE423136T1 AT02804876T AT02804876T ATE423136T1 AT E423136 T1 ATE423136 T1 AT E423136T1 AT 02804876 T AT02804876 T AT 02804876T AT 02804876 T AT02804876 T AT 02804876T AT E423136 T1 ATE423136 T1 AT E423136T1
Authority
AT
Austria
Prior art keywords
csf
biologically active
isolation
stimulating factor
colony stimulating
Prior art date
Application number
AT02804876T
Other languages
English (en)
Inventor
Porekar Vladka Gaberc
Viktor Menart
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Application granted granted Critical
Publication of ATE423136T1 publication Critical patent/ATE423136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02804876T 2001-12-19 2002-12-05 Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor ATE423136T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200100322A SI21102A (sl) 2001-12-19 2001-12-19 Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika

Publications (1)

Publication Number Publication Date
ATE423136T1 true ATE423136T1 (de) 2009-03-15

Family

ID=20433022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804876T ATE423136T1 (de) 2001-12-19 2002-12-05 Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor

Country Status (21)

Country Link
US (1) US20050159589A1 (de)
EP (2) EP2053061A1 (de)
JP (1) JP4454311B2 (de)
KR (1) KR20040071212A (de)
CN (1) CN1606568A (de)
AT (1) ATE423136T1 (de)
AU (1) AU2002366275B2 (de)
BR (1) BR0215191A (de)
CA (1) CA2469984C (de)
DE (1) DE60231243D1 (de)
HR (1) HRP20040572A2 (de)
HU (1) HUP0402547A3 (de)
IL (2) IL162448A0 (de)
MX (1) MXPA04006076A (de)
NO (1) NO20042967L (de)
NZ (1) NZ533305A (de)
PL (1) PL207775B1 (de)
RU (1) RU2358980C2 (de)
SI (2) SI21102A (de)
WO (1) WO2003051922A1 (de)
ZA (1) ZA200404291B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
EP1803464A4 (de) * 2004-09-17 2009-09-09 Cellgentech Inc Topisches präparat zur behandlung von hautgeschwüren
WO2006086822A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
WO2006097944A2 (en) * 2005-03-17 2006-09-21 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP1878739A1 (de) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. Einstufige IMAC (MCAC) Aufreinigung von Proteinen
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
JP2009073819A (ja) * 2007-08-29 2009-04-09 Fujifilm Corp 生理活性物質の精製方法
EP2443135A1 (de) * 2009-06-16 2012-04-25 Lupin Ltd. Verfahren zur aufreinigung von rekombinantem humanem granulozyten-kolonie stimulierendem faktor
EP3366692A1 (de) 2009-06-22 2018-08-29 Amgen, Inc Proteinneufaltung mit einem chemisch gesteuerten redoxzustand
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
KR101951446B1 (ko) * 2010-03-30 2019-02-22 옥타파마 아게 성장 인자 단백질을 정제하는 방법
CN107915769A (zh) 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
CN103215340A (zh) * 2012-01-19 2013-07-24 江苏粒福特生物科技有限公司 一种新颖的粒细胞制备及其抗癌活性检测方法
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
ATE65798T1 (de) 1985-02-08 1991-08-15 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-koloniestimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
KR0133561B1 (ko) * 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5932102A (en) 1998-01-12 1999-08-03 Schering Corporation Immobilized metal, affinity chromatography
FR2796071B1 (fr) * 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes

Also Published As

Publication number Publication date
CA2469984A1 (en) 2003-06-26
PL369669A1 (en) 2005-05-02
AU2002366275A1 (en) 2003-06-30
SI1458757T1 (sl) 2009-10-31
EP1458757B1 (de) 2009-02-18
SI21102A (sl) 2003-06-30
US20050159589A1 (en) 2005-07-21
DE60231243D1 (de) 2009-04-02
KR20040071212A (ko) 2004-08-11
ZA200404291B (en) 2005-08-05
IL162448A0 (en) 2005-11-20
EP1458757A1 (de) 2004-09-22
EP2053061A1 (de) 2009-04-29
CA2469984C (en) 2014-05-20
IL162448A (en) 2010-12-30
RU2358980C2 (ru) 2009-06-20
HUP0402547A3 (en) 2010-01-28
RU2004121982A (ru) 2005-04-20
HUP0402547A2 (hu) 2005-03-29
HK1064681A1 (en) 2005-02-04
WO2003051922A1 (en) 2003-06-26
JP4454311B2 (ja) 2010-04-21
NZ533305A (en) 2005-11-25
NO20042967L (no) 2004-09-07
BR0215191A (pt) 2004-11-16
AU2002366275B2 (en) 2009-04-02
JP2005525304A (ja) 2005-08-25
MXPA04006076A (es) 2005-02-24
CN1606568A (zh) 2005-04-13
HRP20040572A2 (en) 2005-06-30
PL207775B1 (pl) 2011-01-31

Similar Documents

Publication Publication Date Title
ATE423136T1 (de) Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor
DE60014047D1 (de) Verfahren zur reinigung von milchsäure auf industrieller basis
ATE363541T1 (de) Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
EP1273592B1 (de) Verfahren für die Reinigung von Interferon-Proteinen mittels Kationen-Austauschchromatographie
DE50312257D1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
KR960007612A (ko) 재조합 사람 혈청 알부민의 정제방법
NO20050520L (no) Rensingav N,N-dimetylacetamdi
ATE428728T1 (de) Verfahren zur reinigung von erythropoietin
WO2001029078A3 (en) Method for production and use of mite group 1 proteins
DK1714982T3 (da) Fremgangsmåde til rensning af stærkt anioniske proteiner
ATE247665T1 (de) Kombinierter prozess zur reinigung von vancomycin hydrochlorid
Ogura et al. An efficient 1, 3-asymmetric induction accompanied with epimerization at the 2-position. Stereoselective reduction of α-substituted β-keto sulfoxides under basic conditions
EP1244610A4 (de) Verbessertes verfahren zur herstellung von 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin
EP1568705A4 (de) Verfahren und apparat zum einengen und zur aufreinigung von nukleinsäure
DE60233541D1 (de) Verfahren zur Reinigung von 5'-geschützten 2'-Deoxypurin Nukleosiden
NO20052916L (no) Fremgangsmate for rensingen av TNF-bindende proteiner ved anvendelse av IMAC
WO2025186218A8 (en) Purification and analysis of rna
KR930016539A (ko) 재조합 종양괴사인자(TNF-α)의 개선된 정제방법
ES2195259T3 (es) Procedimiento de produccion de (r)-3-hidroxi-4-butirolactona.
DE60201145D1 (de) Verfahren zur Reinigung von 5'-geschützten Thymidinen
JPH11322647A5 (de)
RU95107472A (ru) Способ обработки свинцово-силикатного стекла
DE60131757D1 (de) Verfahren zur reinigung von epi-hne proteinen
MXPA05009153A (es) Proceso para preparar 2-metilpirrolidina y enantiomeros especificos de la misma.
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1458757

Country of ref document: EP